AU2019326423A1 - Collections of peptides, peptide agents, and methods of use thereof - Google Patents

Collections of peptides, peptide agents, and methods of use thereof Download PDF

Info

Publication number
AU2019326423A1
AU2019326423A1 AU2019326423A AU2019326423A AU2019326423A1 AU 2019326423 A1 AU2019326423 A1 AU 2019326423A1 AU 2019326423 A AU2019326423 A AU 2019326423A AU 2019326423 A AU2019326423 A AU 2019326423A AU 2019326423 A1 AU2019326423 A1 AU 2019326423A1
Authority
AU
Australia
Prior art keywords
amino acid
independently
collection
peptide
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019326423A
Other languages
English (en)
Inventor
John Hanney Mcgee
Mark Joseph Mulvihill
Raheleh REZAEI ARAGHI
Ty Matthew Thomson
Gregory L. Verdine
Sebastian Christof Theodor WAHL
Yue-Mei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fog Pharmaceuticals Inc
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of AU2019326423A1 publication Critical patent/AU2019326423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
AU2019326423A 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof Abandoned AU2019326423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719996P 2018-08-20 2018-08-20
US62/719,996 2018-08-20
PCT/US2019/047206 WO2020041270A1 (en) 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019326423A1 true AU2019326423A1 (en) 2021-04-08

Family

ID=69591277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019326423A Abandoned AU2019326423A1 (en) 2018-08-20 2019-08-20 Collections of peptides, peptide agents, and methods of use thereof

Country Status (14)

Country Link
US (1) US12398178B2 (https=)
EP (1) EP3840766A4 (https=)
JP (1) JP2021535108A (https=)
KR (1) KR20210060482A (https=)
CN (1) CN113039195A (https=)
AU (1) AU2019326423A1 (https=)
BR (1) BR112021003113A2 (https=)
CA (1) CA3110082A1 (https=)
EA (1) EA202190531A1 (https=)
IL (1) IL280931A (https=)
MA (1) MA53446A (https=)
MX (1) MX2021001943A (https=)
SG (1) SG11202101672YA (https=)
WO (1) WO2020041270A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds
KR20240031957A (ko) * 2021-06-08 2024-03-08 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
EP2997973A1 (en) 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2685568A1 (en) 2007-05-02 2008-11-13 Dana-Farber Cancer Institute, Inc. Methods of treating diabetes using bad bh3 domain peptide
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
AU2010263056B2 (en) 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2787784A1 (en) 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
EP2590997B1 (en) 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
AU2012242502B2 (en) 2011-04-15 2016-07-28 Dana-Farber Cancer Institute, Inc. Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
CA2851788C (en) 2011-10-11 2022-11-29 Dana-Farber Cancer Institute, Inc. Pyrazol-3-ones that activate pro-apoptotic bax
CA2862391C (en) 2011-12-29 2023-10-10 Loren D. Walensky Stabilized antiviral fusion helices
WO2013142281A1 (en) 2012-03-20 2013-09-26 Dana Farber Cancer Institute, Inc. Inhibition of mcl-1 and/or bfl-1/a1
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3391898A3 (en) 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
AU2014227824B2 (en) 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
EP2970417B1 (en) 2013-03-15 2019-06-19 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
EP2970418A4 (en) 2013-03-15 2016-08-17 Dana Farber Cancer Inst Inc STABILIZED EZH2 PEPTIDES
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
CA2949535C (en) 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
CA2979999A1 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
EP3317294B1 (en) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
CA2995479A1 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
WO2018071076A2 (en) 2016-07-07 2018-04-19 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose
US11034720B2 (en) * 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2021119537A1 (en) 2019-12-11 2021-06-17 Fog Pharmaceuticals, Inc. Technologies useful for assessing permeability
EP4121082A4 (en) 2020-03-17 2024-05-01 Fog Pharmaceuticals, Inc. Helical stapled peptides and uses thereof
AU2021314310A1 (en) 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
WO2022020651A1 (en) 2020-07-22 2022-01-27 Fog Pharmaceuticals, Inc. Amino acids
KR20240031957A (ko) 2021-06-08 2024-03-08 포그 파마슈티컬스 인코포레이티드 스테이플화된 펩티드 및 이의 방법
US20240376151A1 (en) 2022-10-31 2024-11-14 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130217A1 (en) 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
SG11202101672YA (en) 2021-03-30
EP3840766A1 (en) 2021-06-30
MA53446A (fr) 2021-06-30
US12398178B2 (en) 2025-08-26
EP3840766A4 (en) 2022-06-22
WO2020041270A1 (en) 2020-02-27
EA202190531A1 (ru) 2021-08-09
IL280931A (en) 2021-04-29
JP2021535108A (ja) 2021-12-16
US20210179665A1 (en) 2021-06-17
BR112021003113A2 (pt) 2021-05-11
MX2021001943A (es) 2021-07-15
CA3110082A1 (en) 2020-02-27
KR20210060482A (ko) 2021-05-26
CN113039195A (zh) 2021-06-25
WO2020041270A9 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
US11834482B2 (en) Agents modulating beta-catenin functions and methods thereof
JP4629036B2 (ja) アリールアルキルアミン化合物及びその製法
US12398178B2 (en) Collections of peptides, peptide agents, and methods of use thereof
ES2824801T3 (es) Sal de compuesto heterocíclico sustituido con halógeno
JP2021504314A (ja) Ｍｙｓｔファミリーヒストンアセチルトランスフェラーゼ阻害剤
EP4357339A1 (en) Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method therefor, and use thereof
TW201109336A (en) Inhibitors of JNK
CN115353508B (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
US20240376151A1 (en) Stapled peptides and methods thereof
CN112341390B (zh) 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
CN120529912A (zh) 订书钉化肽及其方法
CN120513097A (zh) 订书钉化肽及其方法
CN115322120B (zh) 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
HK40056052A (en) Collections of peptides, peptide agents, and methods of use thereof
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
CN121969627A (zh) 氟烷氧基亚烷基-二氢咪唑并[5,1-d]四嗪酮化合物和相关的化合物及其在治疗医学疾病中的用途
HK40128981A (zh) 订书钉化肽及其方法
HK40108355A (zh) 订书钉化肽及其方法
HK40033762A (en) Agents modulating beta-catenin functions and methods thereof
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
KR101713678B1 (ko) 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물
WO2024131918A1 (zh) 一种取代草酰胺类衍生物、其制备方法及用途
HK40129633A (zh) 苯乙胺和卡西酮及其立体异构体与其前体的制备
BR112016030018B1 (pt) Sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application